Sign inJoin free

Watch / Three stocks for...

Why Jack thinks these stocks could get a boost in the arm

19 Dec 20254:39

Why Jack thinks these stocks could get a boost in the arm

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Key Points:

  • ASX performance trails global markets, with inflation cited as a major headwind

  • Large-cap stocks such as Commonwealth Bank (ASX:CBA), Macquarie Group (ASX:MQG), Wesfarmers (ASX:WES), Goodman Group (ASX:GMG), and CSL (ASX:CSL) saw valuation pressures impact the broader index

  • CSL’s influenza vaccine business faces challenges from reduced vaccination rates post-COVID

  • Artificial intelligence, tariffs, and sticky inflation seen as pivotal themes for 2026

Australian equities have experienced a mixed performance throughout the year, with the domestic market lagging behind global counterparts, according to Jack Stickley from Morgans. Stickley notes the ASX returned around 9% including dividends but still underperformed relative to major markets in the US, Asia, Europe, and emerging regions. He links this to Australia’s slower pace in adjusting interest rates and persistent inflation, which has put the local market at a disadvantage against international peers.

Stickley highlights that much of the past gains in Australian equities were driven by a select group of large-cap names, including Commonwealth Bank (ASX:CBA), Macquarie (ASX:MQG), Wesfarmers (ASX:WES), Goodman Group (ASX:GMG), and CSL (ASX:CSL). As valuations for these stocks stretched, some momentum faded and index performance slowed. While still considered portfolio mainstays, many now trade at long-term averages rather than peak premiums. CSL, Stickley points out, has been especially divisive due to substantial share price declines, with changing influenza vaccination trends and ongoing healthcare pressures contributing to its recent struggles.

Looking to 2026, Stickley identifies artificial intelligence, Trump tariffs, and persistently high inflation as key investment themes. He sees robust capital investment in AI from global giants and anticipates ongoing debate regarding inflationary impacts on gearing and fixed income investments.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy